34results about How to "Inhibits viral replication" patented technology

Contemplated dinucleotide compounds have a general structure of A-B and inhibit synthesis of an RNA-dependent polymerase that initiates RNA replication de novo. In preferred dinucleotides, A comprises a purine or modified purine heterocyclic base and B comprises a pyrimidine or modified pyrimidine heterocyclic base.

The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.

The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.

A method of treating viral infection, such as viral infection caused by a virus of the Coronaviridae family, is provided. A composition having at least oleandrin is used to treat viral infection.

The present invention provides evolved interferon-alpha polypeptides, and conjugates thereof, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.

The present invention is directed to an isolated nucleic acid molecule encoding a fusion polypeptide the expression of which in cells is capable of blocking the entry of HIV-1 into host cells and methods of using the nucleic acid molecule.

A deuterated nucleoside analog of the formulaand the pharmaceutically acceptable salts thereof are provided by this disclosure. The disclosure also includes pharmaceutical compositions comprising a compound or salt of the formula and a carrier. Compounds and salts of this formula are useful for treating viral infections, including HCV infections. A method for treating a host afflicted with hepatitis C or other disorders is also presented that includes administering an effective treatment amount of a nucleoside or nucleotide that has deuterium with at least 50% enrichment at the 5′-position of the nucleoside or nucleotide.

Various tetrahydropyrazolo[1,5-a]pyrimidine compounds, compositions, methods of making, and methods for the prevention and treatment of HCV infections and associated diseases are disclosed. The invention further relates to biomarkers for identification of HCV strains which are resistant to the tetrahydropyrazolo[1,5-a]pyrimidine compounds.

Methods and compositions for treating or preventing virus infections by interfering with the activity or function of Ras, the Ras pathway, the ERK pathway, MEK1 / 2, PKR or eIF-2 alpha, includes the use of agents which inhibit Ras or otherwise modulate anti-PKR activity. Also, a method of diagnosing such virus infections includes the use of cell lines that have an activated Ras pathway, including cell lines which have been transformed with a gene that activates the Ras pathway. The virus infections may be herpes virus infections and HSV-1 or HSV-2 infections in particular.

The present invention concerns the use of an active ingredient selected from the group consisting of agonists of the adenosine receptor system, for inhibiting viral replication in cells. In particular, the invention provides a composition and method for inhibiting viral replication in cells, the method comprising presenting to the cells an effective amount of the active ingredient. According to one embodiment, the adenosine agonist is an A3 receptor agonist (A3RAg). The invention is particularly useful, for although not limited to, inhibiting the replication of HIV virus in human cells.

The invention discloses an antiviral feed Chinese herbal medicine additive for a broiler chicken and a production method thereof. The antiviral feed Chinese herbal medicine additive for broiler chicken consists of the following components in parts by weight: 20-30 parts of radix isatidis, 20-30 parts of milk veteh root, 20-30 parts of herba houttuyniae, 15-25 parts of Glycyrrhiza uralensis, 15-25 parts of Forsythia suspensa and 15-25 parts of epimedium brevicornum. The production method thereof comprises the following steps of: crashing the radix isatidis, milk veteh root, herba houttuyniae, Glycyrrhiza uralensis, Forsythia suspensa and epimedium brevicornum according to parts by weight, and sieving by a 24-mesh sieve; firstly putting the radix isatidis, milk veteh root and herba houttuyniae in a mixing machine for premixing for 5 minutes; then adding the Glycyrrhiza uralensis, Forsythia suspensa and epimedium brevicornum in the mixing machine for mixing for 20 minutes; and finally stopping the machine for discharging the material. The antiviral feed Chinese herbal medicine additive for broiler chicken has the characteristics of strengthening body resistance and eliminating pathogenetic factors, clearing away heat and detoxication, improving antiviral ability, and being low in production cost, simple in production and use and obvious in use effect, and is suitable for 20-29 day-old broiler chicken without adverse reaction.

The present invention is directed to combination therapies for treatment of Human Immunodeficiency Virus (HIV) infection comprising administration of a CCR5 antagonist in combination with other therapeutic agents.

The invention particularly discloses a new method for treating viral infection patients by mesenchymal stem cells. The method comprises the following steps: S1, preparing a mesenchymal stem cell preparation; S2, dividing treatment of viral infection patients into a mesenchymal stem cell treatment group and a reference treatment group; S3, treating viral infection patients in the natural control treatment group according to an original treatment scheme, and meanwhile, introducing the prepared mesenchymal stem cell preparation into the mesenchymal stem cell treatment group for combined treatment; and S4, respectively sampling and analyzing the peripheral blood mononuclear cells of the healed patient in the reference treatment group and the mesenchymal stem cell treatment group. The mesenchymal stem cell preparation is introduced into an original treatment scheme for combined treatment, so that a healed patient has a stronger immune function, the recovery capability of the healed patientis enhanced, virus replication of the healed patient is inhibited, and the influence of cytokine storm is reduced.

The invention discloses a liver disease drug which is used for solving the technical problems of treating liver diseases including hepatitis A, acute hepatitis B, chronic persistent hepatitis, chronic active hepatitis and hepatitis C. The liver disease drug comprises the following components in parts by weight: 1-15000 parts of ants, 1-8000 parts of white atractylodes rhizomes, 0.5-9000 parts of cordyceps sinensis, 1-6000 parts of barbary wolfberry fruits, 1-6000 parts of astragalus mongholicus, 1-4500 parts of Chinese dates, 1-10000 parts of red-rooted salvia roots and 1-5000 parts of Chinese angelica. Compared with the prior art, the liver disease drug is directly absorbed and utilized by the organism in the form of enzyme while all active ingredients and active substances of the ants are kept for promoting hyperplasia of degenerated thymus gland and increasing the weight of degenerated thymus gland to generate interferon in an induced manner, so that white blood cells, T lymphocytes and lysozyme are increased, and therefore, the activity of the interleukin II in killing viruses is obviously enhanced, and hepatitis virus is killed and virus replication is restrained. Besides, the liver disease drug has the effects of nourishing liver and kidney, clearing away heat and toxic materials, soothing the liver and protecting the liver and strengthening the body resistance to eliminate pathogenic factors.

The method includes the steps of cleansing of the scalp sufficiently to remove material which would otherwise block antiviral medication from reaching hair follicles, heating the scalp to increase the absorption of the antiviral medication and applying the antiviral medication to the scalp in effective amount to suppress viral replication or viral activation present in the nerves leading to the scalp.

The present invention provides compositions and methods for inhibiting the replication of influenza virus by administering thiophosphonoformic acid alone or in combination with a neuraminidase inhibitor, for example, oseltamivir.

A plasmid DNA that encodes one or more antigenic genes operably linked to a promoter and a truncated retroviral 3′ LTR exhibits both enhanced safety and acceptable efficiency of expression of antigenic proteins.

An extract for treating hepatitis extracted from the roots or stems of Urticaceae by organic solvents is disclosed. The Urticaceae used in the present invention has a unique sequence of internal transcribed spacer of rDNA, which is at least 70% sequence similarity with that of Boehmeria frutescens, Boehmeria zollingeriana, Urlica thunbergiana, Pilea spp., Boehmeria nivea or Boehmeria densiflora. The extract of the present invention can inhibit the DNA replication of both the wild type hepatitis B virus and the lamivudine-resistant hepatitis B virus.

A method of treating viral infection, such as viral infection caused by a virus of the Coronaviridae family, is provided. A composition having at least oleandrin is used to treat viral infection.

The invention provides a traditional Chinese medicine for preventing influenza. The traditional Chinese medicine comprises crude drugs such as folium isatidis, subprostrate sophora, herba elsholtziae, aleppo avens, platycodon grandiflorum, abrus cantoniensis hance, artemisia apiacea, ginseng leaves, radix angelicae, rhizoma anemarrhenae, manyleaf paris rhizome, burdock, cloves, groundsel, lalang grass rhizome, rhizoma dryopteris crassirhizomae, rheum officinale, radix bupleuri, Chinese barberry roots, semen sojae germinatum, Chinese yams, lonicerae flos, concretio silicea bambusae, rainbow conk, ligusticum and herba epimedii. The traditional Chinese medicine for preventing the influenza can inhibit virus replication, adjust the immune function and realize a broad-spectrum antibacterial effect, has a good effect on prevention of the influenza, is not prone to development of drug resistance and free from toxic and side effects and adverse reactions and can adjust the immune functions of human bodies well.

The present invention relates to methods of treating viral disease using mutagenic nucleoside analogs. In particular, the invention provides 5-aldehydo-uracil nucleosides and derivatives thereof, and methods of administration thereof to increase the virus mutation rate in a virally infected cell.

The present invention relates to a bioactive molecule, herein referred to as the CD8+ suppressor molecule, that is produced by the CD8+ subset of human T-lymphocytes and suppresses type-1 human immunodeficiency virus (HIV-1) replication through inhibition of viral transcription. The invention relates to isolation of clonal CD8+ cells lines that produce the antiviral activity and the development of an assay system for detection of the antiviral activity. The clonal cell lines and the assay system, described herein, may be utilized to purify, characterize and clone the CD8+ suppressor molecule. The CD8+ suppressor molecule may have therapeutic applications for treatment of diseases associated with HIV-1 infection.

The present invention provides evolved interferon-alpha polypeptides, and conjugates thereof, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.

The present invention provides a method of testing for the presence of infectious disease agents or host genetic markers comprising applying a device comprising an absorbent and porous material onto the introitus of a female patient; encouraging air drying of at least a portion of the collected vaginal discharge while the device is proximate to the introitus; and determining the presence of infectious disease agents or host genetic markers in the at least partially dried vaginal discharge.

The invention provides a novel drug targeting delivery adjuvant which is at least one of pentose, hexose, sugar alcohol and disaccharide, wherein the pentose is selected from at least one of xylose and arabinose; the hexose is selected from at least one of glucose, galactose, fructose and mannose; the disaccharide is selected from at least one of sucrose, lactose, maltose and mycose; the sugar alcohol is selected from at least one of sorbitol, mannitol, erythritol, maltitol, lactitol and xylitol. Furthermore, the invention provides an application of the novel drug targeting delivery adjuvant in drug delivery, especially in targeting delivery of antisense oligodeoxynucleotide drugs PMO, PNA, 2'ome RNA (Ribonucleic Acid), peptide-PMO and siRNAs as well as macromolecular plasmids. The adjuvant has a good targeting delivery effect, and is capable of remarkably enhancing the acting effect of a drug in a target tissue; the adjuvant, which is extracted from natural products, namely saccharides, is high in clinical safety index, basically free from hurt to human body, and low in or free from toxic and side effects.

The present invention discloses a targeted exosome based on the RBD region of SARS-CoV-2 S protein and a preparation method thereof. An RBD-VSVG fusion protein is expressed on the targeted exosome of the present invention, and the RBD-VSVG fusion protein is obtained by replacing the extracellular region of VSVG with the RBD of the SARS-CoV-2 S protein. In the present invention, a targeted exosome capable of efficiently and tissue-specifically delivering a potential anti-SARS-CoV-2 medicine is constructed. The targeted exosome is used to encapsulate SARS-CoV-2 siRNA, to specifically inhibit the virus replication in tissues and organs. In a mouse animal model, tail vein injection of exosome encapsulated SARS-CoV-2 siRNA significantly inhibits virus replication in mouse lung tissue and alleviates symptoms such as pneumonia caused by virus infection.